

# Human IgA cross-adsorbed Antibody

Goat Polyclonal

Conjugate FITC

Antigen Affinity Purified

Catalog No. A80-202F

Lot No. A80-202F-4



---

<b>APPLICATIONS</b>	IHC, ICC, F, IF
<b>SPECIES REACTIVITY</b>	Human. Minimum reactivity to mouse and rat
<b>ISOTYPE</b>	IgG
<b>AMOUNT</b>	1 ml at 0.5 mg/ml
<b>STORAGE/SHELF LIFE</b>	2 - 8° C / 1 year from date of receipt
<b>PHYSICAL STATE</b>	Liquid
<b>FLUOROPHORE/PROTEIN</b>	5.8
<b>BUFFER</b>	Phosphate Buffered Saline (PBS) containing 0.2% BSA and 0.09% Sodium Azide
<b>ORIGIN</b>	USA
<b>PRODUCTION PROCEDURES</b>	Antiserum was solid phase adsorbed to ensure class specificity. Antiserum was cross adsorbed using mouse and rat immunosorbents to remove cross reactive antibodies. The antibody to human IgA was isolated by affinity chromatography using antigen coupled to agarose beads and conjugated to fluorescein isothiocyanate (FITC).

Antibody concentration was determined by extinction coefficient: absorbance at 280 nm of 1.4 equals 1.0 mg of IgG.

By immunoelectrophoresis and ELISA this antibody reacts specifically with human IgA. Cross reactivity with IgM and IgG is negligible. No antibody was detected against non-immunoglobulin serum proteins. Less than 1% cross reactivity to mouse and rat IgA was detected. This antibody may cross react with IgA from other species.

**APPLICATIONS** Centrifuge tube to remove product from lid. Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use.

- Immunohistochemistry 1:50 - 1:500
- Immunocytochemistry 1:50 - 1:500
- Flow Cytometry 1:50 - 1:200
- Immunofluorescence 1:50 - 1:500

**APPLICATION NOTES** Not all listed applications have been specifically tested by our laboratory.

**ADDITIONAL INFO** <https://www.bethyl.com/product/A80-202F>  
Use the link above to view SDS, a current list of citations, and other product specific information.

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc.

Eric McIntush, PhD | Chief Scientific Officer

Date: December 3, 2018